中等度から重度の化膿性汗腺炎の研究参加者におけるビメキズマブの長期治療をテストする研究 (BE HEARD EXT)
中等度から重度の化膿性汗腺炎の研究参加者におけるビメキズマブの長期治療を評価する第3相、非盲検、並行グループ、多施設共同、延長研究
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Dublin、アイルランド
- Hs0005 40344
-
-
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35249
- Hs0005 50140
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Hs0005 50175
-
-
California
-
Fountain Valley、California、アメリカ、92708
- Hs0005 50162
-
Los Angeles、California、アメリカ、90045
- Hs0005 50161
-
San Diego、California、アメリカ、92123
- Hs0005 50220
-
Thousand Oaks、California、アメリカ、91320
- Hs0005 50196
-
-
Florida
-
Miami、Florida、アメリカ、33136
- Hs0005 50199
-
North Miami Beach、Florida、アメリカ、33162-4708
- Hs0005 50205
-
Orange Park、Florida、アメリカ、32073
- Hs0005 50152
-
Pembroke Pines、Florida、アメリカ、33028
- Hs0005 50184
-
-
Georgia
-
Sandy Springs、Georgia、アメリカ、30329
- Hs0005 50193
-
Watkinsville、Georgia、アメリカ、30677
- Hs0005 50280
-
-
Indiana
-
Plainfield、Indiana、アメリカ、46168
- Hs0005 50234
-
-
Kentucky
-
Murray、Kentucky、アメリカ、42071
- Hs0005 50425
-
-
Massachusetts
-
Beverly、Massachusetts、アメリカ、01915
- Hs0005 50198
-
Boston、Massachusetts、アメリカ、02215
- Hs0005 50146
-
-
Michigan
-
Clarkston、Michigan、アメリカ、48346
- Hs0005 50178
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Hs0005 50105
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68144
- Hs0005 50194
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89148
- Hs0005 50208
-
-
New Hampshire
-
Newington、New Hampshire、アメリカ、03801
- Hs0005 50159
-
-
New Jersey
-
East Windsor、New Jersey、アメリカ、08520
- Hs0005 50137
-
Verona、New Jersey、アメリカ、07044
- Hs0005 50200
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87102
- Hs0005 50237
-
-
New York
-
New York、New York、アメリカ、10003
- Hs0005 50235
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27516
- Hs0005 50151
-
Durham、North Carolina、アメリカ、27710
- Hs0005 50211
-
Winston-Salem、North Carolina、アメリカ、27157
- Hs0005 50179
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- Hs0005 50177
-
Columbus、Ohio、アメリカ、43213
- Hs0005 50138
-
Columbus、Ohio、アメリカ、43230
- Hs0005 50145
-
Fairborn、Ohio、アメリカ、45324
- Hs0005 50202
-
-
Oklahoma
-
Tulsa、Oklahoma、アメリカ、74137
- Hs0005 50204
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- Hs0005 50147
-
-
Rhode Island
-
Johnston、Rhode Island、アメリカ、02919
- Hs0005 50008
-
Providence、Rhode Island、アメリカ、02903
- Hs0005 50180
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Hs0005 50084
-
Greenville、South Carolina、アメリカ、29615
- Hs0005 50236
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37215
- Hs0005 50142
-
-
Texas
-
Arlington、Texas、アメリカ、76011
- Hs0005 50201
-
Pflugerville、Texas、アメリカ、78660
- Hs0005 50148
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84107
- Hs0005 50141
-
-
Washington
-
Seattle、Washington、アメリカ、98101
- Hs0005 50270
-
-
-
-
-
Leeds、イギリス
- Hs0005 40339
-
-
-
-
-
Catania、イタリア
- Hs0005 40261
-
Roma、イタリア
- Hs0005 40263
-
Rozzano、イタリア
- Hs0005 40258
-
Torino、イタリア
- Hs0005 40330
-
-
-
-
-
Breda、オランダ
- Hs0005 40351
-
Groningen、オランダ
- Hs0005 40292
-
Rotterdam、オランダ
- Hs0005 40264
-
-
-
-
-
Campbelltown、オーストラリア
- Hs0005 30015
-
Carlton、オーストラリア
- Hs0005 30016
-
East Melbourne、オーストラリア
- Hs0005 30011
-
Kogarah、オーストラリア
- Hs0005 30017
-
Parkville、オーストラリア
- Hs0005 30018
-
St Leonards、オーストラリア
- Hs0005 30014
-
Westmead、オーストラリア
- Hs0005 30009
-
Woolloongabba、オーストラリア
- Hs0005 30012
-
-
-
-
-
Barrie、カナダ
- Hs0005 50233
-
Cobourg、カナダ
- Hs0005 50172
-
Edmonton、カナダ
- Hs0005 50135
-
London、カナダ
- Hs0005 50174
-
Richmond Hill、カナダ
- Hs0005 50190
-
Saskatoon、カナダ
- Hs0005 50192
-
Surrey、カナダ
- Hs0005 50133
-
Waterloo、カナダ
- Hs0005 50134
-
Winnipeg、カナダ
- Hs0005 50136
-
-
-
-
-
Athens、ギリシャ
- Hs0005 40251
-
Efkarpia、ギリシャ
- Hs0005 40252
-
-
-
-
-
Geneva、スイス
- Hs0005 40406
-
-
-
-
-
Badalona、スペイン
- Hs0005 40266
-
Barcelona、スペイン
- Hs0005 40159
-
Barcelona、スペイン
- Hs0005 40267
-
Granada、スペイン
- Hs0005 40298
-
Las Palmas de Gran Canaria、スペイン
- Hs0005 40294
-
Madrid、スペイン
- Hs0005 40268
-
Manises、スペイン
- Hs0005 40297
-
Pontevedra、スペイン
- Hs0005 40295
-
Seville、スペイン
- Hs0005 40049
-
Valencia、スペイン
- Hs0005 40230
-
-
-
-
-
Prague、チェコ
- Hs0005 40063
-
Prague、チェコ
- Hs0005 40194
-
-
-
-
-
Antalya、トルコ(Türkiye)
- Hs0005 40270
-
Gaziantep、トルコ(Türkiye)
- Hs0005 40273
-
Istanbul、トルコ(Türkiye)
- Hs0005 40272
-
Izmir、トルコ(Türkiye)
- Hs0005 40271
-
-
-
-
-
Berlin、ドイツ
- Hs0005 40325
-
Berlin、ドイツ
- Hs0005 40326
-
Bochum、ドイツ
- Hs0005 40248
-
Bonn、ドイツ
- Hs0005 40327
-
Darmstadt、ドイツ
- Hs0005 40288
-
Dresden、ドイツ
- Hs0005 40324
-
Dresden、ドイツ
- Hs0005 40356
-
Frankfurt am Main、ドイツ
- Hs0005 40287
-
Hamburg、ドイツ
- Hs0005 40142
-
Hanover、ドイツ
- Hs0005 40328
-
Kiel、ドイツ
- Hs0005 40249
-
Lübeck、ドイツ
- Hs0005 40250
-
Mainz、ドイツ
- Hs0005 40174
-
München、ドイツ
- Hs0005 40323
-
Münster、ドイツ
- Hs0005 40177
-
-
-
-
-
Debrecen、ハンガリー
- Hs0005 40254
-
-
-
-
-
Amiens、フランス
- Hs0005 40197
-
Antony、フランス
- Hs0005 40245
-
Auxerre、フランス
- Hs0005 40321
-
La Rochelle、フランス
- Hs0005 40320
-
Le Mans、フランス
- Hs0005 40355
-
Lyon、フランス
- Hs0005 40247
-
Marseille、フランス
- Hs0005 40130
-
Nice、フランス
- Hs0005 40132
-
Reims、フランス
- Hs0005 40404
-
Rouen、フランス
- Hs0005 40318
-
Saint-Etienne、フランス
- Hs0005 40403
-
Saint-Mandé、フランス
- Hs0005 40246
-
Toulon、フランス
- Hs0005 40285
-
Toulouse、フランス
- Hs0005 40286
-
-
-
-
-
Pleven、ブルガリア
- Hs0005 40313
-
Sofia、ブルガリア
- Hs0005 40284
-
Sofia、ブルガリア
- Hs0005 40311
-
Sofia、ブルガリア
- Hs0005 40314
-
Sofia、ブルガリア
- Hs0005 40315
-
Stara Zagora、ブルガリア
- Hs0005 40353
-
-
-
-
-
Leuven、ベルギー
- Hs0005 40002
-
Woluwe-Saint-Lambert、ベルギー
- Hs0005 40121
-
-
-
-
-
Lodz、ポーランド
- Hs0005 40347
-
Rzeszów、ポーランド
- Hs0005 40293
-
Warsaw、ポーランド
- Hs0005 40335
-
Wroclaw、ポーランド
- Hs0005 40095
-
Wroclaw、ポーランド
- Hs0005 40333
-
Wroclaw、ポーランド
- Hs0005 40334
-
-
-
-
-
Bunkyō City、日本
- Hs0005 20196
-
Fukuoka、日本
- Hs0005 20144
-
Kagoshima、日本
- Hs0005 20195
-
Kurume、日本
- Hs0005 20170
-
Kyoto、日本
- Hs0005 20190
-
Nagoya、日本
- Hs0005 20033
-
Nakagami-gun、日本
- Hs0005 20152
-
Nishinomiya、日本
- Hs0005 20178
-
Obihiro、日本
- Hs0005 20153
-
Osaka、日本
- Hs0005 20037
-
Sapporo、日本
- Hs0005 20154
-
Sendai、日本
- Hs0005 20171
-
tabashi City、日本
- Hs0005 20043
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Study participant has completed the Maintenance Treatment Period through Week 48 in HS0003 (NCT04242446) or HS0004 (NCT04242498), was eligible to receive bimekizumab at the time of completing the feeder study, and did not meet any withdrawal criteria of the feeder study
-
Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
-
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the open-label extension period and for at least 20 weeks after the final dose of investigational medicinal product (IMP)
Exclusion Criteria:
- Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments Note: For any study participant with an ongoing serious adverse event (SAE) from HS0003 (NCT04242446) or HS0004 (NCT04242498), or any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry or a history of serious infections in HS0003 or HS0004, the Medical Monitor must be consulted prior to the study participant's entry into HS0005, although the decision on whether to enroll the participant remains with the Investigator.
- Study participant has a positive or indeterminate interferon-gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated
- Study participant has ongoing or planned use of prohibited hidradenitis suppurativa (HS) or non-HS treatment
- Study participant plans to participate in another study of a medicinal product or device under investigation during this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Bimekizumab dosing regimen 1
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period. |
Subjects will receive bimekizumab at pre-specified time-points.
他の名前:
|
|
実験的:Bimekizumab dosing regimen 2
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period. |
Subjects will receive bimekizumab at pre-specified time-points.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
時間枠:From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. |
From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with treatment-emergent serious adverse events (SAEs) during the study
時間枠:From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:
|
From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
|
Percentage of participants with treatment-emergent adverse events (TEAEs) leading to withdrawal from the study
時間枠:From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported. |
From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
|
Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)
時間枠:Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
HiSCR50 is defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
時間枠:Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
HiSCR75 is defined as at least a 75 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Percentage of participants with Flare
時間枠:Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
Flare is defined as a ≥25 % increase in abscess and inflammatory nodule (AN) count with an absolute increase in AN count of ≥2 relative to Baseline. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Hidradenitis Suppurativa Symptom Questionnaire (HSSQ) Response for Worst Pain
時間枠:Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
The 4 items on the HSSQ assess the study participant's perception of the core symptoms of HS experienced in the past 7 days - pain, smell or odor, drainage or oozing from HS lesions, and itch on an 11-point numeric rating scale with higher scores indicating higher symptom level. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Absolute change from Baseline in Dermatology Life Quality Index (DLQI) Total Score
時間枠:Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
The DLQI is a skin disease specific questionnaire aimed at the evaluation of how the disease affects participants health related quality of life (QOL). The DLQI total score ranges from 0 to 30 with higher scores indicating higher skin disease impact on QOL. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:UCB Cares、001 844 599 2273
出版物と役立つリンク
一般刊行物
- Skrzypczak T, Skrzypczak A, Matusiak L, Szepietowski JC. An evaluation of bimekizumab for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2025 Aug;25(8):811-819. doi: 10.1080/14712598.2025.2522119. Epub 2025 Jun 21.
- Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15.
- Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print.
- Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HS0005
- 2020-004179-42 (EudraCT番号)
- U1111-1307-6132 (その他の識別子:World Health Organization (WHO))
- 2024-511035-10 (レジストリ識別子:EU Clinical Trials)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 共有時間枠
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 共有アクセス基準
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。